Sirolimus-eluting coronary stents in small vessels
|
|
- Julius Miles
- 5 years ago
- Views:
Transcription
1 Interventional Cardiology Sirolimus-eluting coronary stents in small vessels Bernhard Meier, MD, FACC, FESC, a Eduardo Sousa, MD, b Giulio Guagliumi, MD, c Frank Van den Branden, MD, d Ehud Grenadier, MD, e Stephan Windecker, MD, a Hans te Riele, MD, f Vasilis Voudris, MD, g Hélène Eltchaninoff, MD, h Bo Lindvall, MD, i David Snead, PhD, j and Aly Talen, RN, k for the SVELTE Study Group Bern, Switzerland; Sao Paolo, Brazil; Bergamo, Italy; Antwerp, Belgium; Haifa, Israel; Breda, The Netherlands; Athens, Greece; Rouen, France; Stockholm, Sweden; and Warren, NJ Background This prospective multicenter study compared angiographic in-lesion late lumen loss in de novo native coronary artery lesions (vessel diameter range mm, length range z15 to V30 mm) 8 months after the implantation of a sirolimus-eluting stent with that of similar vessels with the same drug-eluting stent or a bare stent of the SIRIUS study (historical controls). Methods and Results One hundred one patients (study group) were matched and compared with 323 patients receiving the bare stent (bare control group) and with 350 receiving the Cypher stent (Cypher control group) in the SIRIUS trial. Mean in-lesion late loss in the study group was lower than that in the bare control group (0.20 versus 0.76 mm, P b.0001) and not inferior to that in the Cypher control group (0.27 mm, P =.3). Adverse event rates (death and myocardial infarction) were similar between groups. At 8 months, target lesion revascularization rates were 0% in the study group, 13.2% in the bare control group ( P b.001), and 4.6% in the Cypher control group ( P =.03). Conclusions The Cypher Bx Velocity stent was confirmed to be superior to the bare Bx Velocity stent in small coronary vessels in terms of in-lesion late loss 8 months after implantation. (Am Heart J 2006;151:1019.e e7.) Rates of angiographic restenosis and target lesion revascularization (TLR) were found to be higher in small vessels (b2.5 mm in diameter) than in larger vessels 6 months after percutaneous transluminal coronary angioplasty or stenting 1,2 and 1 year after stenting. 3 Predictors of small vessel restenosis are diabetes, complex lesions, and long lesions. 1,4,5 Although restenosis has not been conclusively linked to mortality, it can adversely affect quality of life. 6 Stents reduce restenosis by preventing recoil, but tissue growth renarrows the lumen significantly in approximately 20% of patients Small vessel stenting has shown some advantages over balloon angioplasty in randomized and nonrandomized trials but a higher risk for restenosis as compared with larger vessels From the a Swiss Cardiovascular Center Bern, University Hospital, Bern, Switzerland, b Instituto Dante Pazzanese, Sao Paolo, Brazil, c Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy, d Middelheim Ziekenhuis, Antwerp, Belgium, e Rambam Medical Center, Haifa, Israel, f Amphia Ziekenhuis, Breda, The Netherlands, g Onassis Cardiac Center, Athens, Greece, h Hôpital Charles Nicolle, Rouen, France, i Huddinge University Hospital, Stockholm, Sweden, j Cordis Corporation, Warren, NJ, and k Genae Associates, Antwerp, Belgium. This study was supported by a grant from Cordis Corporation, a Johnson & Johnson Company. Submitted May 30, 2005; accepted February 11, Reprint requests: Bernhard Meier, MD, FACC, FESC, University Hospital, Bern 3010, Switzerland. bernhard.meier@insel.ch /$ - see front matter n 2006, Mosby, Inc. All rights reserved. doi: /j.ahj In recent years, stents eluting sirolimus or taxol have attenuated vascular hyperproliferation Sirolimus prevents neointimal proliferation. 26,27 The Cypher (sirolimus-eluting Bx Velocity) stent was compared with the bare Bx Velocity stent in the SIRIUS study (1058 patients) with TLR as the primary end point. Significant reductions ( P b.001) in TLR were demonstrated both at 9 months postprocedure (4% versus 17%, respectively) and 12 months later (5% versus 20%, respectively). 3 Similar results were obtained by recent studies on the implantation of sirolimus-eluting stents in small vessels The small vessel tercile analysis of the SIRIUS Trial revealed that most in-segment restenoses and revascularizations in the sirolimus group occurred in the smallest vessel tercile (mean diameter 2.3 mm). The respective in-segment binary restenoses were 18.6% in the Cypher SIRIUS arm and 42.9% in the bare SIRIUS arm versus 1.9% and 30.2%, respectively, in the large vessel group (mean diameter 3.3 mm). The purpose of this study was to assess the effectiveness of the Cypher stent in reducing in-lesion late loss in de novo native coronary artery lesions in small vessels (diameter range mm). Data for the patients were compared with those for historical control subjects (ie, matched patients in the small vessel tercile of the SIRIUS study), which also allowed an assessment of standardizing and controlling procedural aspects of stenting.
2 1019.e2 Meier et al American Heart Journal May 2006 Methods The study was approved by independent ethics committees and conducted in accordance with Good Clinical Practice, local regulations, and the Declaration of Helsinki. Patients gave their signed consent after the nature of the study had been disclosed to them. All patients were treated with the Cypher stent. The study used adapted stenting techniques to minimize balloon trauma and ensure full coverage of the lesion according to lessons learned from the SIRIUS trial. In addition, the study looked into the efficacy of the treatment by comparing intravascular ultrasound (IVUS) images after stent implantation with those at 8 months. Safety was defined as absence of major adverse cardiac events (MACEs) during follow-up. Study design and eligibility criteria The study was performed at 9 centers in Europe, Israel, and Brazil. The patient inclusion criteria were as follows: (1) stable angina pectoris (Canadian Cardiovascular Society Classifications 1-4), unstable angina pectoris (Braunwald Classifications B and C 1-2), or documented silent ischemia; (2) a single de novo lesion in a small vessel (diameter range z2.25 and V2.75 mm, visual estimate) of a major coronary artery requiring treatment; (3) target lesion stenosis N50% and b100%; (4) target lesion length z15 and V 30 mm; (5) coronary flow NTIMI 1; and (6) willingness to comply with the schedule of follow-up evaluations. Patients with the following conditions were excluded: (1) myocardial infarction within the preceding 24 hours; (2) unprotected left main coronary artery disease with z50% stenosis; (3) significant stenosis (N50%) proximal or distal to the target lesion; (4) ostial target lesion; (5) angiographic evidence of thrombus in the target lesion; (6) heavily calcified lesion; (7) documented left ventricular ejection fraction V30%; (8) excessively tortuous target lesion; and (9) target lesion involving a bifurcation with a diseased side branch z2.25 mm in diameter requiring treatment. Coronary stent procedure The recommended medication was a minimum of 100-mg acetylsalicylic acid 12 hours before the procedure and clopidogrel (loading dose 300 mg before or immediately after the procedure, followed by 75 mg once daily for at least 2 months). Heparin was given as an intravenous bolus during the procedure, with additional boluses to maintain an activated clotting time N250 seconds, and was discontinued within 12 hours. An intracoronary nitroglycerin injection preceded baseline angiography. The addition of glycoprotein IIB/IIIA inhibitors was left at the investigator s discretion. Balloon predilatation was required (no direct stenting). The appropriate balloon size was chosen based on visual estimates of the reference vessel s diameter. A stent system (available as 2.25, 2.50, or 2.75 mm in diameter and as 18, 23, or 33 mm in length) was selected to provide a stent/vessel ratio of 1.1:1 at nominal pressure. The stent was to be at least 3 mm longer than the balloon or the area of predilatation. The goal was to achieve an angiographic appearance of the stent expanded just outside the boundaries of the vessel. Overlap was required if N1 stent was implanted. The deployment pressure was left at the investigator s discretion within the recommended balloon range. In the case of insufficient expansion (N30% final diameter stenosis), the stent could be postdilated with an appropriately sized balloon. Data collection and follow-up The study was monitored by Cordis Clinical Research Europe. Quantitative coronary angiography (QCA) was undertaken by the Brigham and Women s Hospital Angiographic Core Laboratory (Boston, MA); IVUS analysis was performed by the IVUS Cardiovascular Core Analysis Laboratory of the Stanford University School of Medicine (Stanford, CA); and ECG analysis was conducted by the Cardiovascular Data Analysis Center of the Beth Israel Deaconess Medical Center and the Harvard Medical School (Boston, MA). An independent clinical event committee reviewed and adjudicated all major clinical events. Follow-up data were collected at 30 days; 6, 8, and 9 months; as well as 1 year after the procedure, including an angiogram and IVUS imaging to evaluate neointimal growth and remodeling at 8 months. Angiograms at all stages of the study included at least 2 identical orthogonal views. Intravascular ultrasound images using an automated pull-back system and standardized procedures were taken immediately after implantation of the stent and 8 months later. Study end points The primary end point was in-lesion late lumen loss at 8 months measured by QCA. The secondary end points assessed immediately after stent implantation comprised device success (final residual diameter stenosis b50% using the assigned device), lesion success (b50% residual stenosis using any percutaneous method), and procedure success (final diameter stenosis b50% using any percutaneous method, with no death, infarction, or TLR during the hospital stay). At 8 months, the secondary end points assessed in-stent late lumen loss, binary restenosis (z50% diameter stenosis), in-stent minimal lumen diameter, and in-lesion minimal lumen diameter (MLD) by QCA and in-stent volume by IVUS. Secondary clinical end points up to 12 months comprised percutaneous or surgical target vessel revascularization (TVR), target vessel failure (cardiac death, myocardial infarction, or TVR), and a composite of MACEs (death, myocardial infarction, emergent bypass surgery, or repeat TLR). Statistical analysis The analyses included all patients treated with a Cypher stent and all patients in the SIRIUS study whose target vessel characteristics and lesion length satisfied the matching process. Patients with diabetes were matched according to reference vessel diameter (RVD) (small/large) and lesion length (short/long), resulting in 4 blocks with minima of 6 and 5 patients from the SVELTE and SIRIUS studies, respectively, and corresponding maxima of 7 and 65 patients. Patients without diabetes were matched according to RVD (small, medium-small, medium-large, large) and lesion length (short/long), resulting in 12 blocks with minima of 5 and 4 patients from this study and the SIRIUS study, respectively, and corresponding maxima of 7 and 43 patients. The
3 American Heart Journal Volume 151, Number 5 Meier et al 1019.e3 Table I. Patient matching Study group (n = 101) Bare control group (n = 323) P* Cypher control group (n = 350) P y Demographic data Age (y; mean F SE) 61.1 F F F Male [n (%)] 74 (73.3) 213 (65.9) (72.9).7262 Prior infarction [n (%)] 47 (46.5) 93 (29.1) (29.4).0208 Prior bypass surgery [n (%)] 5 (5.0) 33 (10.2) (9.7).0364 Diabetes mellitus [n (%)] 27 (26.7) 97 (30.0) z 95 (27.1) z Hyperlipidemia [n (%)] 83 (82.2) 235 (73.4) (74.6).1801 Hypertension [n (%)] 62 (61.4) 214 (66.5) (68.2).1603 Smoking [past year; n (%)] 36 (36.0) 79 (24.7) (20.2).0011 Angiographic data Preprocedural LAD [n (%)] 50 (49.5) 153 (47.7) (46.6).2467 Type C [n (%)] 23 (22.8) 48 (14.9) (22.9).0344 Thrombus present [n (%)] 11 (10.9) 3 (0.9) b (0.9) b.0001 MLD in-lesion (mean F SE) 0.72 F F F RVD in-lesion (mean F SE) 2.36 F F 0.01 z 2.41 F 0.01 z Lesion length (mean F SE) 14.5 F F 0.2 z 14.6 F 0.2 z Postprocedural Total stent length (mean F SE) 24.4 F F F RVD (mean F SE) 2.39 F F 0.01 b F 0.01 b.0001 MLD (mean F SE) 2.18 F F 0.02 b F 0.02 b.001 Stents implanted (n; mean F SE) 1.15 F F 0.04 b F 0.04 b.0001 In-stent DS (%; mean F SE) 7.8 F F F 0.5 b.0001 LAD, Left anterior descending coronary artery; DS, diameter stenosis. 4Study group compared with bare control. ystudy group compared with Cypher control. zmatching criteria. statistical analysis plan, including the matching process, was prepared before QCA or IVUS data were available. The primary comparison between the Cypher stent and the bare stent was tested by analysis of variance performed on 8-month follow-up data. A test of superiority (two sided: a.05, power N95%) assumed that the Cypher stent would be more effective than the bare stent. The threshold of clinical relevance was a mean reduction of 0.20 mm in-lesion late lumen loss. The Cypher stent in the Svelte study (study group) and Cypher stents in the SIRIUS (Cypher control group) were compared on the primary outcome variable but with a test of noninferiority (one-sided test: a.05, power N85%) which assumed that the standardized procedure would be at least as effective as customary practices. Adverse events were analyzed using the actuarial life table method, with survival estimates using Kaplan-Meier methods and survival comparisons using the Peto-Peto function. Lastly, univariate and stepwise multivariate analyses were performed on all variables to determine prognostic factors and included blocks. Odds ratios were calculated using the Mantel-Haenszel method. All statistical analyses were performed with SAS software (version 8.02) (SAS Institute Inc, Cary, NC). Results Actual target vessel diameters ranged from 1.70 to 3.03 mm in study patients and control subjects. Table I shows that groups were well matched in the 3 variables that defined blocks (diabetes mellitus, RVD, and lesion length). In-lesion and in-stent MLD values of patients with and those without diabetes were almost identical immediately postprocedure; however, 8 months later, the angiographic follow-up data were less satisfactory for patients with diabetes, confirming the known poorer outcomes of the population with diabetes. Mean in-lesion late loss in patients with diabetes (0.32 F 0.46 mm) was almost twice that of patients without diabetes (0.16 F 0.35 mm), and in-stent late loss was greater (0.27 F 0.40 mm vs 0.20 F 0.35 mm, respectively). In-lesion MLD was reduced in patients with diabetes (1.57 F 0.34 mm vs 1.71 F 0.35 mm, respectively); in-lesion restenosis N50% was more frequent (12.5% vs 4.2%, respectively), as was in-stent restenosis (4.2% vs 2.8%, respectively); and neointimal volume was greater (2.08 vs 1.95 mm 3, respectively). Fewer patients with diabetes avoided TVR (89.3% vs 95.6%, respectively) or MACE (85.6% vs 97.3%, respectively). Univariate and multivariate analyses were applied to the Cypher stent QCA data of this cohort at 8 months. Inlesion late loss was predicted by univariate analyses, which showed significant positive relationships with postprocedure RVD, postprocedure in-stent MLD, preprocedure RVD, and a history of diabetes. Multivariate analyses revealed significant positive relationships with postprocedure in-stent MLD and total stent length. The factor total stent length significantly predicted all
4 1019.e4 Meier et al American Heart Journal May 2006 Table II. Efficacy Study group (n = 101) Bare control group (n = 323) Difference* (95% CI) P* Cypher control group (n = 350) Differencey (95% CI) P y Procedural results Lesion success [n (%)] Device success [n (%)] Procedural success [n (%)] Postprocedure In-lesion MLD In-stent MLD 8-M follow-up In-lesion LL In-stent LL In-lesion MLD In-stent MLD In-stent diameter stenosis (%; mean F SE) In-lesion binary restenosis [n (%)] In-stent binary restenosis [n (%)] 101 (100) 323 (100) (99.4) 101 (100) 318 (98.5) (98.6) (98.0) 319 (98.8) (97.1) F F ( 0.29 to 0.15) 2.2 F F ( 0.27 to 0.15) 0.20 F F ( 0.71 to 0.41) 0.22 F F ( 0.91 to 0.60) 1.7 F F (0.23 to 0.53) 2.1 F F (0.49 to 0.82) 15.3 F F ( 32.0 to 20.3) b F ( 0.30 to 0.15) b F ( 0.28 to 0.16) b F ( 0.18 to 0.06) b F ( 0.06 to 0.17) b F ( 0.20 to 0.03) b F ( 0.26 to 0.02) b F (1.2 to 9.8) b.0001 b b (6.3) 83 (39.0) b (11.6) (3.2) 81 (38.0) b (3.9).8232 Clinical outcome at 8 m MACE free (%) TLR free (%) TVR free (%) TVF free (%) LL, late lumen loss; TVF, target vessel failure. 4Study group compared with bare control. ystudy group compared with Cypher control. secondary variables (Table II) in the univariate and multivariate analyses. Significant group differences were present regarding prior myocardial infarction, cigarette smoking during the past year, thrombus and MLD, as well as both postprocedure RVD and in-stent diameter stenosis and were slightly to the disadvantage of the patients in the study group. Slightly more stents were implanted in the control population than in the patients included in the study group. Comparison with bare control subjects Immediate and follow-up results are shown in Table II. Angiographic data at 8 months were available for 94% of the patients (95/101) treated in the study group and for 66% of the subjects (213/323) treated in the bare control group. Postprocedure, mean in-lesion MLD in the study group (1.9 mm) was significantly smaller than that in the bare control group (2.1 mm) (Table II). This reflects the significant preprocedure difference in Table I. However, at the 8-month follow-up, the situation was reversed: mean in-lesion MLD (1.7 mm) was significantly greater in the study group than in the bare control group (1.4 mm) (Table II). A similar reversal between significant results postprocedure and those 8 months later occurred with mean in-stent MLD, such that the study group bare control group difference was 0.21 mm postprocedure and 0.65 mm 8 months later (Table II). Comparison with Cypher control subjects Table I shows that the patients treated with the Cypher stent in this study group or in the Cypher control group were well matched (diabetes mellitus, RVD, and lesion length). The slight mismatches regarding prior myocardial infarction, prior bypass surgery, smoking during the past year, lesion location, American College of
5 American Heart Journal Volume 151, Number 5 Meier et al 1019.e5 Table III. Intravascular ultrasound data Study group (n = 76/66) Bare control group (n = 59/40) P* Cypher control group (n = 75/71) P y Post stent placement (n = 76) EEM area 10.2 F F 0.44 b F EEM volume 233 F F F Stent area 4.6 F F 0.2 b F 1.8 b.0001 Stent volume 105 F F 7.9 b F Minimal plaque volume 126 F F F M follow-up (n = 66) EEM area 10.6 F F F EEM volume 254 F F F Stent area 4.7 F F 0.2 b F Stent volume 115 F F F Minimal plaque volume 141 F F F NIH area 0.03 F F 0.2 b F NIH volume 2.3 F F 4.0 b F EEM, External elastic membrane; NIH, neointimal hyperplasia. 4Study group compared with bare control. ystudy group compared with Cypher control. Cardiology/American Heart Association (ACC/AHA) lesion class, presence of preprocedure thrombus, preprocedure MLD, and 2 postprocedure variables (RVD and in-stent diameter stenosis) disadvantaged patients of the study group. The number of Cypher stents implanted was slightly higher in the SIRIUS cohort than in this study, although mean stent length was similar in all groups. Immediately postprocedure, lesion success, device success, and procedure success were attained for virtually all matched patients (N = 451) with both the study and Cypher control groups (Table II). Angiographic data at 8 months were available for 94% of the patients (95/101) treated in the study group and for 66% of the subjects (232/350) treated in the Cypher control group. The mean in-lesion late loss (primary efficacy variable) was similar for both groups. Target lesion revascularization rates were slightly lower in the study group and approached statistical significance ( P =.0125). Table II shows that the study group was not inferior in efficacy to the Cypher control group. Intravascular ultrasound results Intravascular ultrasound was performed on 100 patients postprocedure in the study group, but only 76 assessments could be analyzed. At 8 months, 91 assessments were performed and 66 assessments were analyzed (Table III). At 8 months, there was a statistically significant ( P b.0001) reduction in the neointimal hyperplasia area in the study group as compared with the control groups. Clinical events Adverse events up to 12 months were rare. There were 2 cases of non Q-wave myocardial infarctions and 3 major bleeding complications in the study group before hospital discharge. Three deaths (3%) and 1 Q-wave myocardial infarction (not involving the target lesions) occurred out of the hospital setting. There had been 4 deaths (1.2%) in the bare control group and 5 (1.4%) in the Cypher control group. The respective frequencies for myocardial infarction were as follows: study group, 3.0%; bare control group, 3.1%; Cypher control group, 2.8%. Repeat interventions Repeat interventions were performed in 3.0% of the study group and in 22.0% of the bare control group ( P b.0001) and 5.7% of the Cypher control group ( P =.1156).
6 1019.e6 Meier et al American Heart Journal May 2006 Discussion The angiography and ultrasound results of all efficacy variables confirmed the findings of the subgroup analysis of the SIRIUS trial showing the Cypher stent to be superior to the bare stent in small coronary arteries at high risk of restenosis. 3 The comparison with the Cypher control group fell within the margin of clinical equivalence, with the mean in-lesion late loss (primary efficacy variable) found to be similar for both groups. The IVUS results showing a statistically significant reduction in the neointimal hyperplasia area in the study group as compared with the control groups suggest that the more rigid implantation policy used in the SVELTE study may have improved outcomes. The study also confirmed the improvements achieved with the Cypher stent versus bare metal stents in patients with diabetes. These findings are similar to those of other randomized controlled trials showing the efficacy of drugeluting stents in small coronary arteries. In the E-SIRIUS trial, 31 patients with de novo lesions (mean vessel diameter 2.55 mm) randomized to treatment with sirolimus-eluting stents had improved outcomes compared with patients treated with bare metal stents: at 8 months, the minimum lumen diameter was significantly higher and restenosis was significantly lower in the sirolimus-eluting stent treated patients. In the C-SIRIUS trial (based on the same protocol as that observed in the E-SIRIUS trial), 32 at 8 months, MLD was significantly higher and TVR was significantly lower in small native coronary arteries implanted with a sirolimus-eluting stent as compared with the control subjects treated with a bare metal stent. In the SES-SMART trial, 30 the mean vessel diameter was even smaller at only 2.2 mm, but the efficacy outcomes at 8 months with the sirolimus-eluting stent were similar to those in the abovementioned studies, with significant reductions in restenosis rates and MACEs. However, recent data from the e-cypher registry, 33 designed to assess sirolimus-eluting stent performance in a real world setting, were not as favorable in small vessels with a diameter V2.5 mm. At 180 days, stent thrombosis and MI were higher compared with larger vessels whereas MACEs and TLR were similar in both groups. Results of the RESEARCH registry 28 showed low rates of angiographic and clinical complications in very small vessels stented with 2.25 mm of sirolimus-eluting stent, although the MLD was significantly lower compared with stents in larger vessels. The long-term outcomes of such registries, together with improvements in angiographic follow-up rates, will help confirm the effectiveness of sirolimuseluting stents in small vessels shown in randomized controlled trials. Study limitations The study had some limitations because of its nonrandomized nature, limited sample size, and the use of historical control groups from the SIRIUS trial, conducted at centers other than those of the present trial. At 8 months of follow-up, angiographic data were only available from 66% of both the bare control and Cypher control groups as compared with 94% of patients in the study group. For the IVUS comparisons at 8 months, data were available from 65% of patients in the study group as compared with only 12% and 20% of the bare control and Cypher control groups, respectively. These significant differences in follow-up rates make it difficult to fully compare the outcomes between the groups. However, patients were matched on 3 major variables (diabetes, RVD, and lesion length), which disadvantaged the study group in variables where they were not well matched. Conclusions The sirolimus-eluting Cypher stent is confirmed to be superior to the bare Bx Velocity stent in terms of inlesion late loss at 8 months in small coronary vessels with a high risk of restenosis. Procedural rigor may have helped decrease the in-lesion late loss assessed by IVUS and the need for TLR. References 1. Hsieh IC, Chien CC, Chang HJ, et al. Acute and long-term outcomes of stenting in coronary vessels N3.0 mm, mm, and b2.5 mm. Catheter Cardiovasc Interv 2001;53: Caputo RP, Flately M, Ho KK, et al. Safety and effectiveness of stent implantation without predilatation for small coronary arteries. Catheter Cardiovasc Interv 2003;59: Holmes Jr DR, Leon MB, Moses JW, et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004;109: Mehilli J, Kastrati A, Dirschinger J, et al. Comparison of stenting with balloon angioplasty for lesions of small coronary vessels in patients with diabetes mellitus. Am J Med 2002;112: Ozdemir M, Timurkaynak T, Tulmac M, et al. Early and late outcome of stenting in a consecutive series of patients with coronary lesions in vessels less than 2.8 mm in diameter. Jpn Heart J 2003;44: Greenberg D, Bakhai A, Cohen DJ. Can we afford to eliminate restenosis? Can we afford not to? J Am Coll Cardiol 2004;43: Froeschl M, Olsen S, Ma X, et al. Current understanding of in-stent restenosis and the potential benefit of drug-eluting stents. Curr Drug Targets Cardiovasc Haematol Disord 2004;4: Dussaillant GR, Mintz GS, Pichard AD, et al. Small stent size and intimal hyperplasia contribute to restenosis: a volumetric intravascular ultrasound analysis. J Am Coll Cardiol 1995;26: Hoffmann R, Mintz GS, Dusaillant GR, et al. Patterns and mechanisms of in-stent restenosis: a serial intravascular ultrasound study. Circulation 1996;94:
7 American Heart Journal Volume 151, Number 5 Meier et al 1019.e7 10. Ellis SG, Shaw RE, Gershony G, et al. Risk factors, time course and treatment effect for restenosis after successful percutaneous transluminal coronary angioplasty of chronic total occlusion. Am J Cardiol 1989;63: Hirshfeld JW Jr, Schwartz JS, Jugo R, et al. Restenosis after coronary angioplasty: a multivariate statistical model to relate lesion and procedure variables to restenosis. J Am Coll Cardiol 1991;18: Lehmann KG, Melkert R, Serruys PW. Contributions of frequency distribution analysis to understanding of coronary restenosis: a reappraisal of the gaussian curve. Circulation 1996;93: Park SW, Lee CW, Hong MK, et al. Randomized comparison of coronary stenting with optimal balloon angioplasty for treatment of lesions in small coronary arteries. Eur Heart J 2000;21: Kastrati A, Schömig A, Dirschinger J, et al. on behalf of the ISAR- SMART Investigators. A randomized trial comparing stenting with balloon angioplasty in small vessels in patients with symptomatic coronary disease. Circulation 2000;102: Koning R, Eltchaninoff H, Commeau P, et al. Stent placement compared with balloon angioplasty for small coronary arteries. Circulation 2001;104: Doucet S, Schalij MJ, Vrolix MCM, et al. Stent placement to prevent restenosis after angioplasty in small coronary arteries. Circulation 2001;104: Al Suwaidi J, Holmes DR, Salam AM, et al. Impact of coronary artery stents on mortality and nonfatal myocardial infarction: meta-analysis of randomized trials comparing a strategy of routine stenting with that of balloon angioplasty. Am Heart J 2004;147: Moreno R, Fernández C, Alfonso F, et al. Coronary stenting versus balloon angioplasty in small vessels. J Am Coll Cardiol 2004;43: Haude M, Konorza TFM, Kalnins U, et al, on behalf of the COAST Investigator. Heparin-coated stent placement for the treatment of stenoses in small coronary arteries of symptomatic patients. Circulation 2003;107: Moer R, Myreng Y, Mblstad P, et al. Stenting in Small Coronary Arteries (SISCA) trial. J Am Coll Cardiol 2001;38: Morice MC, Serruys PW, Sousa JE, et al, on behalf of the RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with standard stent for coronary revascularization. N Engl J Med 2002;346: Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and threedimensional intravascular ultrasound study. Circulation 2001;103: McKeage K, Murcoch D, Goa KL. The sirolimus-eluting stent: a review of its use in the treatment of coronary artery disease. Am J Cardiovasc Drugs 2003;3: Woods TC, Marks AR. Drug-eluting stents. Annu Rev Med 2004;55: Zohlnhofer D, Nuhrenberg TG, Neumann FJ, et al. Rapamycin affects transcriptional programs in smooth muscle cells controlling proliferative and inflammatory properties. Mol Pharmacol 2004;65: Morice M-C, Serruys PW, Sousa JE, et al, for the RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346: Degertekin M, Lemos PA, Lee CH, et al. Intravascular ultrasound evaluation after sirolimus eluting stent implantation for de novo and in-stent restenosis lesions. Eur Heart J 2004;25: Lemos PA, Arampatzis CA, Saia F, et al. Treatment of very small vessels with 2.25-mm diameter sirolimus-eluting stents (from the Research Registry). Am J Cardiol 2004;93: De La Torre Hernandez JM, Burgos V, Gonzalez-Enriquez S, et al. Sirolimus-eluting stents to treat lesions with a high risk of restenosis. Six-month clinical follow-up in the first 100 patients. Rev Esp Cardiol 2004;57: Ardissino D, Cavallini C, Bramucci E, et al. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA 2004;292: Schofer J, Schluter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E_SIRIUS). Lancet 2003;362: Schampaert E, Cohen EA, Schluter M, et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C_SIRIUS). J Am Coll Cardiol 2004;43: Guyon P, Urban P, Schofer J, et al. The impact of sirolimus-eluting stent implantation in small vessel angioplasty: a report from the e-cypher Registry. J Am Coll Cardiol 2005;45 (Suppl 1):64A.
Journal of the American College of Cardiology Vol. 47, No. 7, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 47, No. 7, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.05.102
More informationLesions at coronary bifurcations represent a challenging
Randomized Study to Evaluate Sirolimus-Eluting Stents Implanted at Coronary Bifurcation Lesions Antonio Colombo, MD; Jeffrey W. Moses, MD; Marie Claude Morice, MD; Josef Ludwig, MD; David R. Holmes, Jr,
More informationJournal of the American College of Cardiology Vol. 46, No. 5, by the American College of Cardiology Foundation ISSN /05/$30.
Journal of the American College of Cardiology Vol. 46, No. 5, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.06.009
More informationDRUG ELUTING STENTS. Cypher Versus Taxus: Are There Differences? Introduction. Methods SIGMUND SILBER, M.D., F.E.S.C., F.A.C.C.
DRUG ELUTING STENTS Cypher Versus Taxus: Are There Differences? SIGMUND SILBER, M.D., F.E.S.C., F.A.C.C. From the Cardiology Practice and Hospital, Munich, Germany Today, drug-eluting stents (DES) are
More informationBIOFREEDOM: Polymer free Biolimus A9 eluting
TCTAP 2011 Seoul, April 27 29, 2011 BIOFREEDOM: Polymer free Biolimus A9 eluting Stents and Paclitaxel eluting stents Eberhard Grube MD, FACC, FSCAI Hospital Oswaldo Cruz - Dante Pazzanese, São Paulo,
More informationHCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal?
HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February 2014 Drug-eluting stents Are they all equal? Vassilis Spanos Interventional Cardiologist, As. Director 3 rd Cardiology Clinic Euroclinic
More informationClinical Investigations
Clinical Investigations Clinical Outcomes for Single Stent and Multiple Stents in Contemporary Practice Qiao Shu Bin, MD; Liu Sheng Wen, MD; Xu Bo, BS; Chen Jue, MD; Liu Hai Bo, MD; Yang Yue Jin, MD; Chen
More informationLong-Term Clinical Outcomes With Sirolimus-Eluting Coronary Stents
Journal of the American College of Cardiology Vol. 50, No. 14, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.06.029
More informationPCI for In-Stent Restenosis. CardioVascular Research Foundation
PCI for In-Stent Restenosis ISR of BMS Patterns of In-Stent Restenosis Pattern I : Focal Type IA: Articulation / Gap Type IB: Marginal Type IC: Focal body Type ID: Multifocal Pattern II,III,IV : Diffuse
More informationLM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
More informationSirolimus-Eluting Stents for Treatment of In-Stent Restenosis
Clinical Investigation Alfonso Medina, MD José Suárez de Lezo, MD Manuel Pan, MD Antonio Delgado, MD José Segura, MD Djordje Pavlovic, MD Francisco Melián, MD Miguel Romero, MD Federico Segura, MD Enrique
More informationJournal of the American College of Cardiology Vol. 48, No. 2, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 48, No. 2, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.03.039
More information2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center
2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium Does Lt Late Cth Catch up Exist Eiti in DES? : Quantitative Coronary Angiography Analysis Kyung Woo Park, MD Cardiovascular
More informationEffect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
More informationCoronary Heart Disease. Treatment of Left Anterior Descending Coronary Artery Disease With Sirolimus-Eluting Stents
Coronary Heart Disease Treatment of Left Anterior Descending Coronary Artery Disease With Sirolimus-Eluting Stents Neil Sawhney, MD; Jeffrey W. Moses, MD; Martin B. Leon, MD; Richard E. Kuntz, MD; Jeffrey
More informationCulprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome
Culprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome Hiroyuki Okura*, MD; Nobuya Matsushita**,MD Kenji Shimeno**, MD; Hiroyuki Yamaghishi**, MD Iku Toda**,
More informationDESolve NX Trial Clinical and Imaging Results
DESolve NX Trial Clinical and Imaging Results Alexandre Abizaid, MD, PhD, Instituto Dante Pazzanese, Sao Paulo, Brazil On behalf of the DESolve Nx Trial Investigators Please refer to the TCT2014 App or
More informationPCI for Long Coronary Lesion
PCI for Long Coronary Lesion Shift of a General Idea with the Introduction of DES In the Bare Metal Stent Era Higher Restenosis Rate With Increasing Stent Length and Decreasing Stent Area Restenosis.6.4.2
More informationPROMUS Element Experience In AMC
Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical
More informationPCI for Left Anterior Descending Artery Ostial Stenosis
PCI for Left Anterior Descending Artery Ostial Stenosis Why do you hesitate PCI for LAD ostial stenosis? LAD Ostial Lesion Limitations of PCI High elastic recoil Involvement of the distal left main coronary
More informationNine-year clinical outcomes of drug-eluting stents vs. bare metal stents for large coronary vessel lesions
Journal of Geriatric Cardiology (2017) 14: 35 41 2017 JGC All rights reserved; www.jgc301.com Research Article Open Access Nine-year clinical outcomes of drug-eluting stents vs. bare metal stents for large
More informationDES in Diabetic Patients
DES in Diabetic Patients Charles Chan, M.D., FACC Gleneagles Hospital Singapore TCT ASIA PACIFIC 2007 Why do diabetics have worse outcome after PCI? More extensive atherosclerosis and diffuse disease Increase
More informationAngiographic and Intravascular Ultrasound Predictors of In-Stent Restenosis
1630 JACC Vol. 32, No. 6 Angiographic and Intravascular Ultrasound Predictors of In-Stent Restenosis SHUNJI KASAOKA, MD, JONATHAN M. TOBIS, MD, FACC, TATSURO AKIYAMA, MD,* BERNHARD REIMERS, MD,* CARLO
More informationUnprotected LM intervention
Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline
More informationC. W. Hamm, B. Cremers, H. Moellmann, S. Möbius-Winkler, U. Zeymer, M. Vrolix, S. Schneider, U. Dietz, M. Böhm, B. Scheller
Paclitaxel-Eluting PTCA-Balloon in Combination with the Coroflex Blue Stent vs the Sirolimus Coated Cypher Stent in the Treatment of Advanced Coronary Artery Disease C. W. Hamm, B. Cremers, H. Moellmann,
More informationIn-Stent Restenosis. Can we kill it?
In-Stent Restenosis Can we kill it? However, In-stent Restenosis is the most serious problem (2-25%) More than 15, lesions will need treatment because of in-stent restenosis. Varying Prevalence Rates of
More informationKomplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents
Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents Prof. Dr. med. Julinda Mehilli Medizinische Klinik und Poliklinik I Klinikum der Universität München Campus Großhadern Key Factors
More informationOne-year Outcome of Stenting for Long Coronary Lesions, a Prospective Clinical Trial
Tabriz University of Medical Sciences Original Article One-year Outcome of Stenting for Long Coronary Lesions, a Prospective Clinical Trial Samad Ghaffari MD, Mohammad Reza Hasanian MD, Leili Pourafkari
More informationDeclaration of conflict of interest. Nothing to disclose
Declaration of conflict of interest Nothing to disclose Hong-Seok Lim, Seung-Jea Tahk, Hyoung-Mo Yang, Jin-Woo Kim, Kyoung- Woo Seo, Byoung-Joo Choi, So-Yeon Choi, Myeong-Ho Yoon, Gyo-Seung Hwang, Joon-Han
More informationKey Words Angioplasty Coronary artery disease Revascularization Stent drug eluting stent
J Cardiol 26 Dec; 48 6 : 325 331 3 mm : Initial and Mid-Term Effects of 3 mm Long Sirolimus-Eluting Stents in Patients With Diffuse Long Coronary Lesions: Comparison With Bare Metal Stents Abstract Yosuke
More informationISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions
Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main
More informationjournal of medicine The new england Sirolimus-Eluting and Paclitaxel-Eluting Stents for Coronary Revascularization abstract
The new england journal of medicine established in 1812 august 18, 2005 vol. 353 no. 7 Sirolimus-Eluting and Paclitaxel-Eluting Stents for Coronary Revascularization Stephan Windecker, M.D., Andrea Remondino,
More informationEXPERIMENTAL AND THERAPEUTIC MEDICINE 6: , 2013
840 Identification of independent risk factors for restenosis following bare metal stent implantation: Role of bare metal stents in the era of drug eluting stents CHANG BUM PARK 1 and HOON KI PARK 2 1
More informationDES In-stent Restenosis
DES In-stent Restenosis Roxana Mehran, MD Columbia University Medical Center The Cardiovascular Research Foundation DES Restenosis Mechanisms Predictors Morphological patterns Therapy approach Mechanisms
More informationLate Loss Is The Single Best Parameter For Estimating Stent-Based Restenosis Resistance
Late Loss Is The Single Best Parameter For Estimating Stent-Based Restenosis Resistance Richard Kuntz Brigham and Women s s Hospital Harvard Medical School Late Loss and DES Brief history of Late Loss
More informationAre Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) &
Are Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) & Biomatrix TM Single Center Experience (Indonesia)(Final 5 Yr F up) T. Santoso University of
More informationPredictors of 6-Month Angiographic Restenosis inside Bare-Metal Stent in Chinese Patients with Coronary Artery Disease
Original Article Acta Cardiol Sin 2009;25:1 6 Coronary Artery Disease Predictors of 6-Month Angiographic Restenosis inside Bare-Metal Stent in Chinese Patients with Coronary Artery Disease Yung-Lung Chen,
More informationDrug eluting stents From revolution to evolution. Current limitations
Drug eluting stents From revolution to evolution Current limitations Eric Eeckhout Centre Hospitalier Universitaire Vaudois Lausanne - Switzerland eric.eeckhout@chuv.ch Overview Historical perspective
More informationAbstract Background: Methods: Results: Conclusions:
Two-Year Clinical and Angiographic Outcomes of Overlapping Sirolimusversus Paclitaxel- Eluting Stents in the Treatment of Diffuse Long Coronary Lesions Kang-Yin Chen 1,2, Seung-Woon Rha 1, Yong-Jian Li
More informationINDEX 1 INTRODUCTION DEVICE DESCRIPTION CLINICAL PROGRAM FIRST-IN-MAN CLINICAL INVESTIGATION OF THE AMAZONIA SIR STENT...
May 2017 INDEX 1 INTRODUCTION... 2 2 DEVICE DESCRIPTION... 3 ANTI-PROLIFERATIVE DRUG - SIROLIMUS... 3 BIODEGRADABLE POLYMERS... 3 SIROLIMUS CONTROLLED ELUTION... 4 STENT PLATFORM... 4 3 CLINICAL PROGRAM...
More informationJournal of the American College of Cardiology Vol. 39, No. 8, by the American College of Cardiology Foundation ISSN /02/$22.
Journal of the American College of Cardiology Vol. 39, No. 8, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)01774-6
More informationSuperiority of sirolimus eluting stent compared with intracoronary b radiation for treatment of in-stent restenosis: a matched comparison
1584 INTERVENTIONAL CARDIOLOGY AND SURGERY Superiority of sirolimus eluting stent compared with intracoronary b radiation for treatment of in-stent restenosis: a matched comparison E Iofina, P W Radke,
More informationPrevention of Coronary Stent Thrombosis and Restenosis
Prevention of Coronary Stent Thrombosis and Restenosis Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea 9/12/03 Coronary
More informationTCTAP Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI
Indian TUXEDO Trial In Medically Treated Diabetics Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI Executive Director and Dean Escorts Heart Institute & Medical Research Center and Fortis Hospitals, New Delhi
More informationResolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program
Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program Prof. Ran Kornowski, MD, FESC, FACC Director - Division of Interventional Cardiology Rabin Medical Center and Tel Aviv University,
More informationUpdate on stents: Recent studies on the TAXUS stent system in small vessels
REVIEW Update on stents: Recent studies on the TAXUS stent system in small vessels Shuzou Tanimoto Joost Daemen Patrick W Serruys Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands Abstract:
More informationFinal Clinical and Angiographic Results From a Nationwide Registry of FIREBIRD Sirolimus- Eluting Stent: Firebird In China (FIC) Registry (PI R. Gao)
The Microport FIREBIRD Polymer-based Sirolimus- Eluting Stent Clinical Trial Program Update: The FIC and FIREMAN Registries Junbo Ge, MD, FACC, FESC, FSCAI On behalf of Runlin Gao (FIC PI) and Haichang
More informationPerspective of LM stenting with Current registry and Randomized Clinical Data
Asian Pacific TCT Perspective of LM stenting with Current registry and Randomized Clinical Data Patrick W. Serruys MD PhD Yoshinobu Onuma MD Seung-Jung Park MD, PhD 14:48-15:00, 2009 Symposium Arena, Level
More informationSignificant Reduction in Restenosis After the Use of Sirolimus-Eluting Stents in the Treatment of Chronic Total Occlusions
Journal of the American College of Cardiology Vol. 43, No. 11, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.01.045
More informationNobori Clinical Studies Up-dates. Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy
Nobori Clinical Studies Up-dates Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy Drug Eluting Stents High benefit in preventing restenosis and improving quality of life
More informationCYPHER (Polymer-based Sirolimus-eluting DES) New Stent Platforms. Campbell Rogers, M.D. Chief Technology Officer
Ground breaking, Life changing CYPHER (Polymer-based Sirolimus-eluting DES) New Stent Platforms Campbell Rogers, M.D. Chief Technology Officer Disclosure Statement of Financial Interest I am a full-time
More informationResults of the Washington Radiation for In-Stent Restenosis Trial for Long Lesions (Long WRIST) Studies
Intracoronary Radiation Therapy Improves the Clinical and Angiographic Outcomes of Diffuse In-Stent Restenotic Lesions Results of the Washington Radiation for In-Stent Restenosis Trial for Long Lesions
More informationDrug eluting stents. Where are we now and what can we expect in 2003? Tony Gershlick Leicester
Drug eluting stents Where are we now and what can we expect in 2003? Tony Gershlick Leicester Trials Real World What we need i. Prevent restenosis cost effective Either : - Treat all at equivalent cost
More informationThe publication in January 2001 of the first-in-man
MINI-REVIEW: EXPERT OPINIONS Drug-Eluting Stents Cost Versus Clinical Benefit Pedro A. Lemos, MD; Patrick W. Serruys, MD, PhD; J. Eduardo Sousa, MD, PhD The publication in January 2001 of the first-in-man
More informationDrug Filled Stent Optical Coherence Tomography Results from RevElution Trial Stent Strut Coverage and Stent Apposition
Drug Filled Stent Optical Coherence Tomography Results from RevElution Trial Stent Strut Coverage and Stent Apposition Prof Martin Rothman on behalf of Dr. Stephen G. Worthley Alexandre Abizaid, Ajay J
More informationFor Personal Use. Copyright HMP 2013
Case Report J INVASIVE CARDIOL 2013;25(2):E39-E41 A Case With Successful Retrograde Stent Delivery via AC Branch for Tortuous Right Coronary Artery Yoshiki Uehara, MD, PhD, Mitsuyuki Shimizu, MD, PhD,
More informationA Meta-Analysis Of Randomized Controlled Trials With Coronary Drug-Eluting Stents Compared With Bare-Metal Stents
ISPUB.COM The Internet Journal of Cardiology Volume 3 Number 2 A Meta-Analysis Of Randomized Controlled Trials With Coronary Drug-Eluting Stents Compared With Bare-Metal Stents M Sondhi, A Jagannath, J
More informationDespite its benefit over balloon angioplasty in patients
Coronary Heart Disease Quantitative Assessment of Angiographic Restenosis After Sirolimus-Eluting Stent Implantation in Native Coronary Arteries Jeffrey J. Popma, MD; Martin B. Leon, MD; Jeffrey W. Moses,
More informationNew Generation Drug- Eluting Stent in Korea
New Generation Drug- Eluting Stent in Korea Young-Hak Kim, MD, PhD Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Purpose To briefly introduce the
More informationDr. Robert J. van Geuns. Thoraxcenter ErasmusMC Rotterdam On behalf of Dr. Jean Fajadet and Co-investigators
Complex coronary bifurcation lesions treated with the novel polymer-free dedicated bifurcation paclitaxel-eluting stent (Nile pax): clinical and angiographic results of the prospective, multicenter bipax
More informationCoronary drug-eluting stents (DES) were first approved
Thrombosis in Coronary Drug-Eluting Stents Report From the Meeting of the Circulatory System Medical Devices Advisory Panel of the Food and Drug Administration Center for Devices and Radiologic Health,
More informationThree-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G.
Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G. Ellis MD Dean J. Kereiakes MD and Gregg W. Stone MD for the ABSORB
More informationBioabsorbable Scaffolding: Technology and Clinical Update. PD Dr. Nicolas Diehm, MD, FESC Inselspital, University Hospital Bern, Switzerland
Bioabsorbable Scaffolding: Technology and Clinical Update PD Dr. Nicolas Diehm, MD, FESC Inselspital, University Hospital Bern, Switzerland Disclosures I am not Ron Waksman 1 Clinical experience with AMS
More informationIn-stent Restenosis Diagnostic and Therapeutic Challenges. Kostis Raisakis General Hospital of Athens «G. Gennimatas»
In-stent Restenosis Diagnostic and Therapeutic Challenges Kostis Raisakis General Hospital of Athens «G. Gennimatas» Introduction With POBA, rates of acute and chronic vessel occlusion at 30% to 60%, secondary
More informationInfluence of Planned Six-Month Follow-Up Angiography on Late Outcome After Percutaneous Coronary Intervention A Randomized Study
Journal of the American College of Cardiology Vol. 38, No. 4, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01476-0 Influence
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST In the last five years, I received research grants or speaker fees or I am/was consultant for: Abbott Vascular, Asahi, Astra Zeneca, AVI, Boston Scientific, Biotronik,
More informationEXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017
EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017 Igor F. Palacios, MD Director of Interventional Cardiology Professor of Medicine Massachusetts
More informationeluting Stents The SPIRIT Trials
Everolimus-eluting eluting Stents The SPIRIT Trials Gregg W. Stone, MD Columbia University Medical Center Cardiovascular Research Foundation Abbott XIENCE V Everolimus-eluting eluting Stent Everolimus
More informationJournal of the American College of Cardiology Vol. 48, No. 2, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 48, No. 2, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.01.080
More informationStent Thrombosis in Bifurcation Stenting
Summit TCT Asia Pacific 2009 Stent Thrombosis in Bifurcation Stenting Associate Professor Tan Huay Cheem MBBS, M Med(Int Med), MRCP, FRCP(UK), FAMS, FACC, FSCAI Director, National University Heart Centre,
More informationT wo drug eluting stents are approved by the US Food and
650 INTERVENTIONAL CARDIOLOGY AND SURGERY Efficacy of drug eluting stents in patients with and without diabetes mellitus: indirect comparison of controlled trials C Stettler, S Allemann, M Egger, S Windecker,
More informationComparison of Sirolimus Versus Paclitaxel Eluting Stents for Treatment of Coronary in-stent Restenosis F. Airoldi, et al. Am J Cardiol (2006)
Comparison of Sirolimus Versus Paclitaxel Eluting Stents for Treatment of Coronary in-stent Restenosis F. Airoldi, et al. Am J Cardiol (2006) 97;1182-7 n&list_uids=16616023 Value of the American College
More informationSeQuent Please World Wide Registry
Journal of the American College of Cardiology Vol. 6, No. 18, 212 212 by the American College of Cardiology Foundation ISSN 735-197/$36. Published by Elsevier Inc. http://dx.doi.org/1.116/j.jacc.212.7.4
More informationBiolimus-Eluting Stent With Biodegradable Polymer Versus Sirolimus-Eluting Stent With Durable Polymer: A Randomised, Non-Inferiority Trial
Limus Eluted From A Durable vs ERodable Stent Coating Biolimus-Eluting Stent With Biodegradable Polymer Versus Sirolimus-Eluting Stent With Durable Polymer: A Randomised, Non-Inferiority Trial Stephan
More informationStenting In Small Coronary Arteries (SISCA) Trial A Randomized Comparison Between Balloon Angioplasty and the Heparin-Coated bestent
Journal of the American College of Cardiology Vol. 38, No. 6, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01602-3 Stenting
More informationCoronary artery disease (CAD) is the REVIEW PROJECTED HEALTH AND ECONOMIC BENEFITS OF THE USE OF SIROLIMUS-ELUTING CORONARY STENTS
PROJECTED HEALTH AND ECONOMIC BENEFITS OF THE USE OF SIROLIMUS-ELUTING CORONARY STENTS Rodolphe Ruffy, MD, FACC,* and Raymond J. Kaden, MBA, CPA ABSTRACT Despite remarkable technological progress in interventional
More informationSafety and Efficacy of Coronary Stent Implantation. Acute and Six Month Outcomes of 1,126 Consecutive Patients Treated in 1996 and 1997
Original Article Safety and Efficacy of Coronary Stent Implantation. Acute and Six Month Outcomes of 1,126 Consecutive Patients Treated in 1996 and 1997 Luiz Alberto Mattos, Ibraim Pinto, Alexandre Abizaid,
More informationThe MAIN-COMPARE Study
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationInspiron Stent. Clinical Research Program. Pedro A. Lemos MD PhD. Heart Institute InCor University of Sao Paulo Medical School Sao Paulo Brazil
Stent Clinical Research Program Pedro A. Lemos MD PhD Heart Institute InCor University of Sao Paulo Medical School Sao Paulo Brazil All faculty disclosures are available on the CRF Events App and online
More informationPrimary and mid-term outcome of sirolimus-eluting stent implantation with angiographic guidance alone
Journal of Cardiology (2008) 51, 18 24 Primary and mid-term outcome of sirolimus-eluting stent implantation with angiographic guidance alone Hajime Fujimoto, Susumu Tao, Tomotaka Dohi, Sachiko Ito, Jun
More informationSKG Congress, 2015 EVOLVE II. Stephan Windecker
SKG Congress, 2015 EVOLVE II Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland BIODEGRADABLE POLYMER DES Stefanini,
More informationBasics of Angiographic Interpretation Analysis of Angiography
Basics of Angiographic Interpretation Analysis of Angiography Young-Hak Kim, MD, PhD Cardiac Center, University of Ulsan College of Medicine, Seoul, Korea What made us nervous Supervisors Stent Contrast
More informationRationale for Percutaneous Revascularization ESC 2011
Rationale for Percutaneous Revascularization Marie Claude Morice, Massy FR MD, FESC, FACC ESC 2011 Paris Villepinte - 27-31 August, 2011 Massy, France Potential conflicts of interest I have the following
More informationContemporary Percutaneous Coronary Intervention Versus Balloon Angioplasty for Multivessel Coronary Artery Disease
Contemporary Percutaneous Coronary Intervention Versus Balloon Angioplasty for Multivessel Coronary Artery Disease A Comparison of the National Heart, Lung and Blood Institute Dynamic Registry and the
More informationThe Clinical Evaluation of the Medtronic AVE Driver Coronary Stent System
The Clinical Evaluation of the Medtronic AVE Driver Coronary Stent System A prospective, multicenter, non randomized study to evaluate the safety and efficacy of the Medtronic AVE Driver Coronary Stent
More informationDrug-Coated Balloons for Small Coronary Artery Disease: BASKET-SMALL 2
Drug-Coated Balloons for Small Coronary Artery Disease: BASKET-SMALL 2 Raban V. Jeger,Ahmed Farah, Marc-Alexander Ohlow, Norman Mangner, Sven Möbius-Winkler, GregorLeibundgut, Daniel Weilenmann, JochenWöhrle,
More informationOutcomes With the Paclitaxel-Eluting Stent in Patients With Acute Coronary Syndromes Analysis From the TAXUS-IV Trial
Journal of the American College of Cardiology Vol. 45, No. 8, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.10.074
More informationThe Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) Trial
Journal of the American College of Cardiology Vol. 47, No. 2, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.10.045
More informationJournal of the American College of Cardiology Vol. 47, No. 8, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 47, No. 8, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.11.066
More informationPercutaneous Intervention of Unprotected Left Main Disease
Percutaneous Intervention of Unprotected Left Main Disease Technical feasibility and Clinical outcomes Seung-Jung Park, MD, PhD, FACC Professor of Internal Medicine Asan Medical Center, Seoul, Korea Unprotected
More informationEffectiveness of Drug-Eluting Stents in Patients With Bare-Metal In-Stent Restenosis
Journal of the American College of Cardiology Vol. 49, No. 5, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.10.049
More informationA Randomized Comparison of Clopidogrel and Aspirin Versus Ticlopidine and Aspirin After the Placement of Coronary Artery Stents
Journal of the American College of Cardiology Vol. 41, No. 6, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)02974-1
More informationWhat is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation?
What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation? Keun-Ho Park, Myung Ho Jeong, Min Goo Lee, Jum Suk Ko,
More informationJournal of the American College of Cardiology Vol. 34, No. 4, by the American College of Cardiology ISSN /99/$20.
Journal of the American College of Cardiology Vol. 34, No. 4, 1999 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00324-1 Final
More informationJournal of the American College of Cardiology Vol. 57, No. 12, by the American College of Cardiology Foundation ISSN /$36.
Journal of the American College of Cardiology Vol. 57, No. 12, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2010.10.041
More informationOriginal Research Clinical Outcomes of Drug-Eluting Stents Compared with Bare Metal Stents in Our Routine Clinical Practice
Hellenic J Cardiol 2008; 49: 132-138 Original Research Clinical Outcomes of Drug-Eluting Stents Compared with Bare Metal Stents in Our Routine Clinical Practice MOHAMMAD ALIDOOSTI, MOJTABA SALARIFAR, ALI
More informationLessons learned From The National PCI Registry
Lessons learned From The National PCI Registry w a v e On Behalf of The Publication Committee of the National PCI Registry Objectives & Anticipated Achievements To determine the epidemiology of patients
More informationIVUS Assessment of the Mechanism of In-stent Restenosis? Gary S. Mintz, MD Cardiovascular Research Foundation
IVUS Assessment of the Mechanism of In-stent Restenosis? Gary S. Mintz, MD Cardiovascular Research Foundation SURE Trial: Restenosis in non-stented lesions Average of the two image slices with the smallest
More information